BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Telecommute Arrangement: What's Pivotal for Your Efficiency? - 2Guaranteeing Quality Medical care with Federal medical care Benefit Plans.
- 3Eurovision Song Contest changes voting rules after controversial allegations against Israel
- 45 Great High-Mileage Electric Vehicles Of 2024
- 5Traveling Alone: An Excursion of Self-Disclosure
- Step by step instructions to Streamline Your Dozing Involvement in a Savvy Bed
- Well known Worldwide Caf\u00e9s to Experience
- Grasping the Course of Evacuation and Extradition in U.S. Migration
- Ukrainian foreign minister appeals for funds for drones
- Must-See Attractions in Washington, D.C.
- Here are 10 stores where you can get a free Thanksgiving turkey
- The most effective method to Quick Track Your Outcome in Advanced Showcasing with a Web-based Degree
- More than 800 flights canceled as FAA cuts traffic at 40 major airports. Here's what to know.
- Step by step instructions to Utilize Open Record Rewards for Your Potential benefit
